Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

3.21
Delayed Data
As of Jan 13
 -0.06 / -1.83%
Today’s Change
3.16
Today|||52-Week Range
9.02
-21.32%
Year-to-Date
Is the Options Market Predicting a Spike in Merrimack (MACK) Stock?
Jan 11 / Zacks.com - Paid Partner Content
Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016
Jan 09 / MotleyFool.com - Paid Partner Content
Company News for January 10, 2017
Jan 10 / Zacks.com - Paid Partner Content
Why Merrimack Pharmaceuticals Stock Is Roaring Higher Today
Jan 09 / MotleyFool.com - Paid Partner Content
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
Jan 09 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close3.27
Today’s open3.29
Day’s range3.16 - 3.33
Volume4,001,047
Average volume (3 months)3,990,695
Market cap$416.1M
Dividend yield--
Data as of 01/13/2017

Growth & Valuation

Earnings growth (last year)-66.25%
Earnings growth (this year)+12.28%
Earnings growth (next 5 years)+5.61%
Revenue growth (last year)-13.14%
P/E ratioNM
Price/Sales9.86
Price/Book--

Competitors

 Today’s
change
Today’s
% change
KPTIKaryopharm Therapeut...-0.13-1.27%
AVDLAvadel Pharmaceutica...-0.02-0.20%
AQXPAquinox Pharmaceutic...+0.14+0.79%
CTMXCytomX Therapeutics ...+0.15+1.31%
Data as of 01/13/2017

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)-$0.22
Annual revenue (last year)$89.3M
Annual profit (last year)-$148.0M
Net profit margin-165.76%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Gary L. Crocker
Head-
Corporate Operations
William M. McClements
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs